EA201290107A1 - Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии - Google Patents
Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапииInfo
- Publication number
- EA201290107A1 EA201290107A1 EA201290107A EA201290107A EA201290107A1 EA 201290107 A1 EA201290107 A1 EA 201290107A1 EA 201290107 A EA201290107 A EA 201290107A EA 201290107 A EA201290107 A EA 201290107A EA 201290107 A1 EA201290107 A1 EA 201290107A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sustainable
- methods
- gene expression
- expression profiles
- determining
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 230000014509 gene expression Effects 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 101150010487 are gene Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000002493 microarray Methods 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27704609P | 2009-09-18 | 2009-09-18 | |
| US27838709P | 2009-10-06 | 2009-10-06 | |
| GBGB0917457.4A GB0917457D0 (en) | 2009-10-06 | 2009-10-06 | Method |
| PCT/EP2010/063751 WO2011033095A1 (en) | 2009-09-18 | 2010-09-17 | Method for identifying whether a patient will be responder or not to immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201290107A1 true EA201290107A1 (ru) | 2012-10-30 |
Family
ID=41393894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201290107A EA201290107A1 (ru) | 2009-09-18 | 2010-09-17 | Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110070268A1 (https=) |
| EP (1) | EP2478116A1 (https=) |
| JP (1) | JP2013505008A (https=) |
| KR (1) | KR20130055553A (https=) |
| CN (1) | CN102597269A (https=) |
| AU (1) | AU2010297248A1 (https=) |
| BR (1) | BR112012006088A2 (https=) |
| CA (1) | CA2773666A1 (https=) |
| EA (1) | EA201290107A1 (https=) |
| GB (1) | GB0917457D0 (https=) |
| IL (1) | IL218313A0 (https=) |
| MX (1) | MX2012003329A (https=) |
| SG (1) | SG179129A1 (https=) |
| WO (1) | WO2011033095A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014151026A1 (en) * | 2013-03-15 | 2014-09-25 | Myriad Genetics, Inc. | Genes and gene signatures for diagnosis and treatment of melanoma |
| WO2016003810A1 (en) | 2014-07-02 | 2016-01-07 | Myriad Genetics, Inc. | Genes and gene signatures for diagnosis and treatment of melanoma |
| JP2018503373A (ja) * | 2014-12-30 | 2018-02-08 | ジェネンテック， インコーポレイテッド | がんの予後診断及び治療のための方法及び組成物 |
| CN109416925A (zh) * | 2016-05-05 | 2019-03-01 | 南托米克斯有限责任公司 | 检查点失效和使检查点失效的方法 |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| EP4121964A1 (en) * | 2020-03-17 | 2023-01-25 | Regeneron Pharmaceuticals, Inc. | Methods and systems for determining responders to treatment |
| EP4161658A4 (en) * | 2020-06-01 | 2024-10-02 | Dana-Farber Cancer Institute, Inc. | Methods for modulating mhc-i expression and immunotherapy uses thereof |
| CN115495026B (zh) * | 2022-11-21 | 2023-03-10 | 杭州字节方舟科技有限公司 | 一种优化内存处理方法、装置、设备及存储介质 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| ATE509102T1 (de) | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| PT1053325E (pt) | 1998-02-05 | 2006-05-31 | Glaxosmithkline Biolog Sa | Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao. |
| US7049302B1 (en) | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
| HUP0105303A2 (en) | 1999-01-29 | 2002-05-29 | Corixa Corp | Her-2/neu fusion proteins |
| TR200102781T2 (tr) | 1999-03-11 | 2002-01-21 | Smithkline Beecham Biologicals S. A. | Yeni bileşikler |
| DE60014076T2 (de) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
| CZ303468B6 (cs) | 2000-02-23 | 2012-10-03 | Smithkline Beecham Biologicals S. A. | Imunogenní smes a farmaceutická smes |
| US20020076469A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
| DE10127572A1 (de) * | 2001-05-30 | 2002-12-05 | Pathoarray Gmbh | Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen |
| US7229774B2 (en) * | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| AU2002360525A1 (en) * | 2001-12-06 | 2003-06-23 | University Of Florida | Targeting leukemia cells |
| EP1482795B1 (en) | 2002-02-04 | 2009-11-11 | Corixa Corporation | New immunoeffector compounds |
| US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| IL165372A0 (en) | 2002-06-11 | 2006-01-15 | Glaxosmithkline Biolog | Immunodenic compositions |
| US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| WO2004076565A2 (en) * | 2003-02-25 | 2004-09-10 | Technical Knockout, Inc. | Improved coated weight plates, dumbbells and method of manufacture |
| WO2004078035A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Expression profiles for breast cancer and methods of use |
| US20050095607A1 (en) * | 2003-03-07 | 2005-05-05 | Arcturus Bioscience, Inc. University Of Louisville | Breast cancer signatures |
| US20060265138A1 (en) | 2003-03-14 | 2006-11-23 | David Bowtell | Expression profiling of tumours |
| US20040241725A1 (en) * | 2003-03-25 | 2004-12-02 | Wenming Xiao | Lung cancer detection |
| US7598287B2 (en) * | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| WO2004111603A2 (en) * | 2003-05-28 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| JP4724657B2 (ja) | 2003-05-30 | 2011-07-13 | アストラゼネカ ユーケー リミテッド | プロセス |
| EP1651775A2 (en) * | 2003-06-18 | 2006-05-03 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
| EP1980629A3 (en) * | 2003-08-28 | 2008-12-17 | Ipsogen | Identification of an erbb2 gene expression signature in breast cancers |
| CA2540894A1 (en) * | 2003-10-03 | 2005-04-14 | Bayer Pharmaceuticals Corporation | Gene expression profiles and methods of use |
| WO2005044999A2 (en) * | 2003-11-05 | 2005-05-19 | New England Medical Center Hospitals, Inc. | Treatment with immunoregulatory t cells |
| JP4974528B2 (ja) * | 2004-02-09 | 2012-07-11 | 扶桑薬品工業株式会社 | 核酸検出方法およびその利用 |
| US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
| WO2005108610A2 (en) * | 2004-04-05 | 2005-11-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for the selection of subjects for multiple sclerosis therapy |
| US7332281B2 (en) * | 2004-04-27 | 2008-02-19 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| CA2587676A1 (en) | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
| MX2007006441A (es) | 2004-11-30 | 2007-08-14 | Johnson & Johnson | Prognosis de cancer de pulmon. |
| US20070059720A9 (en) * | 2004-12-06 | 2007-03-15 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
| US7666595B2 (en) | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
| GB0504302D0 (en) | 2005-03-02 | 2005-04-06 | Univ Dublin | Markers for melanoma |
| US20080193938A1 (en) | 2005-04-01 | 2008-08-14 | Yu Kun | Materials And Methods Relating To Breast Cancer Classification |
| US20090186024A1 (en) | 2005-05-13 | 2009-07-23 | Nevins Joseph R | Gene Expression Signatures for Oncogenic Pathway Deregulation |
| US20070111257A1 (en) * | 2005-07-07 | 2007-05-17 | Kohne David E | Improved protein expression comparison assay results and applications |
| CA2650507A1 (en) * | 2006-04-27 | 2007-11-08 | Universite De Montreal | Assessment and reduction of risk of graft-versus-host disease |
| EP2032719A2 (en) * | 2006-06-02 | 2009-03-11 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
| US20100167302A1 (en) * | 2007-09-10 | 2010-07-01 | Novartis Ag | Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy |
| WO2009068621A1 (en) * | 2007-11-30 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Method for classifying cancer patients as responder or non-responder to immunotherapy |
-
2009
- 2009-10-06 GB GBGB0917457.4A patent/GB0917457D0/en not_active Ceased
-
2010
- 2010-09-17 AU AU2010297248A patent/AU2010297248A1/en not_active Abandoned
- 2010-09-17 CN CN2010800494497A patent/CN102597269A/zh active Pending
- 2010-09-17 JP JP2012529295A patent/JP2013505008A/ja not_active Ceased
- 2010-09-17 BR BR112012006088-0A patent/BR112012006088A2/pt not_active IP Right Cessation
- 2010-09-17 CA CA2773666A patent/CA2773666A1/en not_active Abandoned
- 2010-09-17 EA EA201290107A patent/EA201290107A1/ru unknown
- 2010-09-17 MX MX2012003329A patent/MX2012003329A/es not_active Application Discontinuation
- 2010-09-17 US US12/884,407 patent/US20110070268A1/en not_active Abandoned
- 2010-09-17 KR KR1020127009956A patent/KR20130055553A/ko not_active Withdrawn
- 2010-09-17 EP EP10757757A patent/EP2478116A1/en not_active Ceased
- 2010-09-17 WO PCT/EP2010/063751 patent/WO2011033095A1/en not_active Ceased
- 2010-09-17 SG SG2012017869A patent/SG179129A1/en unknown
-
2012
- 2012-02-26 IL IL218313A patent/IL218313A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013505008A (ja) | 2013-02-14 |
| IL218313A0 (en) | 2012-04-30 |
| BR112012006088A2 (pt) | 2020-08-11 |
| AU2010297248A1 (en) | 2012-04-12 |
| EP2478116A1 (en) | 2012-07-25 |
| CA2773666A1 (en) | 2011-03-24 |
| CN102597269A (zh) | 2012-07-18 |
| KR20130055553A (ko) | 2013-05-28 |
| WO2011033095A1 (en) | 2011-03-24 |
| GB0917457D0 (en) | 2009-11-18 |
| MX2012003329A (es) | 2012-04-20 |
| SG179129A1 (en) | 2012-05-30 |
| US20110070268A1 (en) | 2011-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200802242A1 (ru) | Способ определения того, будет или не будет пациент респондером на иммунотерапию | |
| EA201290107A1 (ru) | Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии | |
| EA201391074A1 (ru) | Профили экспрессии генов рака толстой кишки и способы применения | |
| WO2013182912A3 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| EP3683320A3 (en) | Mirna fingerprint in the diagnosis of lung cancer | |
| CA2840149C (en) | Methods and nucleic acids for determining the prognosis of a cancer subject | |
| HK1213946A1 (zh) | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 | |
| PH12015501744A1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
| UA110790C2 (uk) | Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні | |
| WO2011094335A3 (en) | Microrna signatures predicting responsiveness to anti-her2 therapy | |
| IN2012DN04944A (https=) | ||
| WO2012174256A3 (en) | Dna methylation profiles in cancer | |
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| EA201791577A1 (ru) | СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III | |
| EA201291195A1 (ru) | Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1 | |
| EP4435112A3 (en) | Compositions and methods for screening solid tumors | |
| EA201300470A1 (ru) | Антитела | |
| BR112012020373A8 (pt) | anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico | |
| WO2011122857A3 (ko) | 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트 | |
| UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
| EA201890649A1 (ru) | Новые биомаркеры и способы лечения рака | |
| MX2013004747A (es) | Marcadores de gen de sangre periferica para el diagnostico temprano de la enfermedad de parkinson. | |
| WO2011021177A3 (en) | Compositions and methods for prognosis and treatment of prostate cancer | |
| WO2013087929A3 (de) | Verfahren zur identifizierung von markersequenzen für gynäkologisches malignom | |
| WO2012166700A3 (en) | Molecular profiling of a lethal tumor microenvironment |